Analysts Set Target Price of $115.40 for Bright Minds Biosciences

Bright Minds Biosciences Inc. (NASDAQ:DRUG) has received a consensus recommendation of “Moderate Buy” from eight research firms currently covering the company. According to Marketbeat.com, analysts have set an average 12-month target price of $115.40 for the stock, reflecting a positive outlook among market observers.

Of the eight analysts, one has rated the stock with a hold recommendation, while seven have issued buy recommendations. Recent reports highlight the varying target prices set by different firms, indicating a range of confidence in the company’s future performance. For example, Robert W. Baird established a target price of $142.00 on January 7, 2024. Meanwhile, Cantor Fitzgerald reiterated an “overweight” rating, maintaining optimism about the company’s prospects.

On the other hand, Zacks Research recently downgraded Bright Minds from a “strong-buy” rating to a “hold” on December 2, 2023. In contrast, HC Wainwright reaffirmed a “buy” rating and set a target price of $115.00 in a report dated December 30, 2023. Additionally, BTIG Research raised its price target from $72.00 to $147.00 on January 6, 2024, also issuing a “buy” rating.

Institutional Investments Reflect Confidence

The trading activity surrounding Bright Minds Biosciences indicates growing interest from institutional investors. Notable transactions include the Police & Firemen’s Retirement System of New Jersey, which acquired a new stake valued at approximately $28,000 in the second quarter.

In a significant move, JPMorgan Chase & Co. increased its stake by 624.3% during the same period, now holding 2,173 shares worth about $57,000. Other institutional players such as Russell Investments Group Ltd. and MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. have also entered new positions, valued at approximately $58,000 and $66,000, respectively.

Overall, hedge funds and institutional investors collectively own 40.52% of Bright Minds Biosciences’ stock, indicating solid confidence in the company’s future.

About Bright Minds Biosciences

Bright Minds Biosciences Inc., trading under the symbol DRUG, is a clinical-stage biotechnology firm focused on developing innovative small-molecule therapeutics aimed at treating mental health and neurodegenerative disorders. The company utilizes proprietary chemistry platforms to create serotonin-modulating and neuroprotective compounds inspired by psychedelic structures.

With a mission to address significant unmet medical needs, Bright Minds is developing treatments for conditions such as major depressive disorder, post-traumatic stress disorder, and Alzheimer’s disease. The company’s lead candidate, BMB-101, is currently under clinical development as an oral treatment for mood and anxiety disorders.

As Bright Minds continues to navigate through its clinical development phases, analysts and investors alike are closely monitoring its progress and potential market impact.